Health

Novartis Raises Peak Sales Targets for Key Cancer Drugs

The Novartis campus in Basel, Switzerland.Photographer: Stefan Wermuth/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Fabienne Kinzelmann

November 20, 2025 at 6:23 AM UTC

Updated on

November 20, 2025 at 8:06 AM UTC

Novartis AG boosted its sales targets for two key cancer drugs, underscoring confidence in its oncology pipeline.

The Swiss drugmaker raised its peak sales guidance for breast cancer drug Kisqali to at least $10 billion from $8 billion, it said Thursday. It lifted its forecast for leukemia therapy Scemblix to at least $4 billion from $3 billion.